Conference Speaker Spotlight: Norman Stockbridge, M.D., Ph.D.

2018-06-20T16:00:31+00:00 June 20th, 2018|

The Pulmonary Hypertension Association (PHA) Scientific Sessions Planning Committee has announced Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Products (DCaRP) in the Center for Drug Evaluation and Research of the Food and Drug Administration (FDA), as a speaker at PHA’s 2018 International PH Conference and Scientific Sessions. DCaRP is responsible

Conference Speaker Spotlight: Sagar Lonial, M.D., FACP

2018-06-15T20:23:38+00:00 June 15th, 2018|

Prompted by recent successes in the field of oncology in precision medicine, the Pulmonary Hypertension Association’s (PHA) Scientific Sessions Committee has invited Sagar Lonial, M.D., FACP, an internationally-recognized leading authority in multiple myeloma treatment and research, to provide his insight in the field of PH to health care providers. Dr. Lonial’s research has focused

PHA-Funded Research Discovers Link Between Cancer Protein and Fibrosis in PAH Patients

2018-06-15T20:26:20+00:00 June 15th, 2018|

A new molecular mechanism in the development of World Health Organization (WHO) Group 1 pulmonary hypertension (PH) – pulmonary arterial hypertension (PAH) – has been discovered by investigators from the Brigham and Women’s Hospital, through work funded in part by the Pulmonary Hypertension Association (PHA). NEDD9, a protein that was discovered in 1992 and has

Pediatric Focus at PHA’s 2018 International PH Conference and Scientific Sessions

2018-06-08T19:19:29+00:00 June 7th, 2018|

Steven H. Abman, M.D. David B. Frank, M.D., Ph.D. Stephanie Siehr Handler, M.D. Uyen Truong, M.D. Erika S. Berman Rosenzweig, M.D. Despite recent milestones in the field of pediatric PH, knowledge and treatment options still lag behind that of adult PH. This year’s

Conference Speaker Spotlight: Michael Snyder, Ph.D.

2018-06-01T17:00:29+00:00 May 21st, 2018|

Because genetics are essential to the discussion about precision medicine, the Scientific Sessions Committee is excited to feature Michal Snyder, Ph.D., Stanford Ascherman professor and chair of Genetics and director of the Center of Genomics and Personalized Medicine at Stanford University School of Medicine, during the session block “Omics and Wearable in Pulmonary Hypertension:

Early Intervention: Better Clinical and Economic Outcomes

2018-05-09T18:26:10+00:00 May 9th, 2018|

by Phyllis Hanlon, Contributing Writer   Researchers who study WHO Group 1 PH (PAH, pulmonary arterial hypertension) have shown that drugs may delay progression of the disease, reduce symptoms and improve quality of life. More recently, scientists have found that using more than one drug early when a patient is newly diagnosed can produce an even

Diagnosing and Treating Older Patients with PH: A Complex Process

2018-05-09T18:01:42+00:00 May 9th, 2018|

by Phyllis Hanlon, Contributing Writer   In 2016, the Population Reference Bureau released a report that projects the number of people age 65 and older will more than double from 46 million currently to over 98 million by 2060. Age can bring many changes in health and physical conditions. According to the National Council on

Study Looks at HIV and Pulmonary Hypertension

2018-05-03T17:28:11+00:00 May 3rd, 2018|

by Phyllis Hanlon, Contributing Writer   Pulmonary hypertension, or high blood pressure in the lungs, has been associated with a number of different conditions including heart disease, liver disease, lupus and scleroderma. Research indicates that people with HIV are also at risk for developing PH, a serious condition that affects the heart and lungs. A 2017

Nadine Al-Naamani, M.D., M.S., Aldrighetti Research Award for Young Investigators Grant Recipient, Shares Research Journey and Hope for the Future

2018-04-13T14:26:59+00:00 April 11th, 2018|

Nadine Al-Naamani, M.D., M.S., University of Pennsylvania, and Andrew Sweatt, M.D., Stanford University, were the research awardees of the 2017 Aldrighetti Research Award for Young Investigators and PHA/ATS Research Fellowship in Pulmonary Arterial Hypertension, respectively. In this two-part series, the 2017 PHA Research Program awardees detail their journey to PH, and their hopes for

Study Finds Inhaled Nitric Oxide May Benefit Patients with COPD and Pulmonary Hypertension

2018-04-11T15:26:35+00:00 April 11th, 2018|

by Phyllis Hanlon, Contributing Writer   The Centers for Disease Control and Prevention (CDC) reports that about 15.7 million people in the U.S. have been diagnosed with chronic obstructive pulmonary disease (COPD). The CDC noted in 2014 that this disease was the third leading cause of death in the U.S. Previous research has estimated that between